Differential effects of low dose CP122,288 and eletriptan on Fos expression due to stimulation of the superior sagittal sinus in cat

Pain

Volumn 82, Issue 1, 1999, Pages 15-22

  Goadsby, Peter J ^a   Hoskin, Karen L ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Headache; Migraine; Serotonin; Trigeminal

Indexed keywords

5 METHYLAMINOSULFONYLMETHYL 3 (1 METHYL 2 PYRROLIDINYLMETHYL) 1H INDOLE; ELETRIPTAN; MANNITOL; PROTEIN C FOS; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAT; CONTROLLED STUDY; EXTRAVASATION; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; NOCICEPTIVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; SUPERIOR SAGITTAL SINUS; TRIGEMINAL NUCLEUS;

ANIMALS; CATS; CRANIAL SINUSES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; INDOLES; NEURONS; PROTO-ONCOGENE PROTEINS C-FOS; PYRROLIDINES; SEROTONIN AGONISTS; STIMULATION, CHEMICAL; SUMATRIPTAN; TRIGEMINAL NEURALGIA; TRYPTAMINES; VASOCONSTRICTOR AGENTS;

EID: 0033023781     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(99)00025-1     Document Type: Article

References (76)

1. Berman, A.L., The brain stem of the cat, a cytoarchitectonic atlas with stereotaxic co-ordinates, University of Wisconsin Press, London, 1968.
2. Bou J., Domenech T., Gras J., Beleta J., Llenas J., Fernandez A.G., Palacios J.M. Pharmacological profile of almotriptan, a novel antimigraine agent. Cephalalgia. 17:1997;421-422.
3. Brandli P., Loffler B.M., Breu V., Osterwalder R., Maire J.P., Clozel M. Role of endothelin in mediating neurogenic plasma extravasation in rat aura mater. Pain. 64:1996;315-322.
4. Buzzi M.G., Moskowitz M.A. The antimigraine drug, sumatriptan (GR43 175) selectively blocks neurogenic plasma extravasation from blood vessels in aura mater. Br. J. Pharmacol. 99:1990;202-206.
5. Buzzi M.G., Moskowitz M.A., Shimizu T., Heath H.H. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology. 3C:1991;1193-1200.
6. Buzzi M.G., Sakas D.E., Moskowitz M.A. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat aura mater. Eur. J Pharmacol. 165:1989;251-258.
7. Clements J.R., Magnusson K.R., Hautman J., Beitz A.J. Rat tooth pull projections to spinal trigeminal subnucleus caudalis are glutamate-like immunoreactive. J. Comp. Neurol. 309:1991;281-288.
8. Connor, H.E., Bertin, L., Gillies, S., Beattie, D.T., Ward, P. and The GR205171 Clinical Study Group, Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine, Cephalalgia, 18 (1998) 392.
9. Connor H.E., Feniuk W., Beattie D.T., North P.C., Oxford A.W., Saynor D.A., Humphrey P.P.A. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia. 17:1997;145-152.
10. Cosolo W.C., Martinello P., Louis W.J., Christophidis N. Blood-brain barrier disruption using mannitol: time course and electron microscopy studies. Am J. Physiol. 256:1989;R443-R447.
11. Couch J.R., Saper J., Meloche J.P. Treatment of migraine with BMS180048: response at 2 hours. Headache. 36:1996;523-530.
12. Cumberbatch M.J., Hill R.G., Hargreaves R.J. Rizatriptan has central antinociceptive effects against aurally evoked responses. Eur. J. Pharmacol. 328:1997;37-40.
13. Diener, H.C., Substance-P antagonist RPR100893-201 is not effective in human migraine attacks. In: J. Olesen and P. Tfelt-Hansen (Eds.), Proceedings of the 6th International Headache Seminar, Lippincott-Raven, New York, 1996.
14. Dimitriadou V., Buzzi M.G., Moskowitz M.A., Theoharides T.C. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat aura mater mast cells. Neuroscience. 44:1991;97-112.
15. Dimitriadou V., Buzzi M.G., Theoharides T.C., Moskowitz M.A. Ultrastructural evidence for neurogenically mediated changes in blood vessel; of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience. 48:1992;187-203.
16. Edvinsson L., Goadsby P.J. Neuropeptides in headache. Eur. J. Neurol. 5:1998;329-341.
17. Gallai V., Sarchielli P., Floridi A., Franceschini M., Codini M., Trequattrini A., Palumbo R. Vasoactive peptides levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 15:1995;384-390.
18. Goadsby, P.J., Bench to bedside: what have we learnt recently about headache?, Curr. Opin. Neurol., 10 (1997a) 215-220.
19. Goadsby, P.J., Current concepts of the pathophysiology of migraine. In: N.T. Mathews (Ed.), Neurologic Clinics of North America, Vol. 15, W.B. Saunders, Philadelphia, 1997b, pp. 27-41.
20. IB/lD agonists in migraine: comparative pharmacology and its therapeutic implications. CNS Drugs. 10:1998;271-286.
21. Goadsby P.J., Adner M., Edvinsson L. Characterization of endothelin ETA receptors in the cerebral vasculature and their lack of effect upon spreading depression. J. Cereb. Blood Flow Metabol. 16:1996;698-704.
22. Goadsby P.J., Duckworth J.W. Effect of stimulation of trigeminal ganglion or regional cerebral blood flow in cats. Am. J. Physiol. 253:1987;R270-R274.
23. Goadsby P.J., Edvinsson L. The trigeminovascular system and migraine: studies characterising cerebrovascular and neuropeptide changes seen in man and cat. Ann. Neurol. 33:1993;48-56.
24. Goadsby P.J., Edvinsson L., Ekman R. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann. Neurol. 23:1988;193-196.
25. Goadsby P.J., Edvinsson L., Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28:1990;183-187.
26. Goadsby P.J., Hoskin K.L. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)-1-D receptor agonist zolmitriptan (311C90): are brain stem sites a therapeutic target in migraine? Pain. 67:1996;355-359.
27. Goadsby P.J., Hoskin K.L., Knight Y.E. Substance P blockade with the potent and centrally acting antagonist GR205171 does not effect central trigeminal activity with superior sagittal sinus stimulation. Neuroscience. 86:1998;337-343.
28. IB/lD receptors. Br. J. Pharmacol. 122:1997;918-922.
29. Goadsby P.J., Lambert G.A., Lance J.W. Stimulation of the trigeminal ganglion increases flow in the extracerebral but not the cerebral circulation of the monkey. Brain Res. 381:1986;63-67.
30. Goadsby, P.J. and Silberstein, S.D., Headache. In: A. Asbury and C.D. Marsden (Eds.), Blue Books in Practical Neurology, Vol. 17, Butterworth-Heinemann, New York, 1997.
31. Goadsby P.J., Zagami A.S., Lambert G.A. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache. 31:1991;365-371.
32. Goldstein D.J., Wang O., Saper J.R., Stoltz R., Silberstein S.D., Mathew N.T. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia. 17:1997;785-790.
33. Gupta P., Brown D., Butler P., Closier M.D., Dickinson R.P., Ellis P., James K., Macor J.E., Rigby J.W., Shepper on N.B., Wythes M.J. Preclinical in vivo pharmacology of eletriptan (UK 116,044): a potent and selective partial agonist at the 5HT1D-like receptor. Cephalalgia. 16:1996;386.
34. Gupta P., Brown D., Butler P., Ellis P., Grayson K.L., Land G.C., Macor J.E., Robson S.F., Wythes M.J., Shepperson N.B. The in vivo pharmacological profile of a 5-HT1 receptor agonist, CPI 22,288, a selective inhibitor of neurogenic inflammation. Br. J. Pharmacol. 116:1995;2385-2390.
35. Hammond D.L., Presley R., Gogas K.R., Bausbaum A.I. Morphine suppressed Fos protein-like immunoreactivity in the spinal cord and nucleus tractus solitarii evoked by a noxious visceral stimulus in the rat. J. Comp. Neurol. 315:1992;244-253.
36. Hartig P.R., Hoyer D., Humphrey P.P.A., Martin G.R. Alignment of receptor nomenclature with the human genome: classification of 5-HT-1B and 5-HT-1D receptor subtypes. Trends Pharmacol. Sci. 17:1996;103-105.
37. Hoskin K.L., Goadsby P.J. CP122,288 has no effect on c-fos expression in the trigeminal nucleus caudalis after superior sagittal sinus stimulation. Cephalalgia. 17:1997;402.
38. Hoskin K.L., Kaube H., Goadsby P.J. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain. 119:1996;1419-1428.
39. Humphrey P.P.A., Goadsby P.J. Controversies in headache, The mode of action of sumatriptan is vascular? A debate, Cephalalgia. 14:1994;401-410.
40. Jackson N.C. A comparison of oral eletriptan (UK-116,044) (20-80 mg) and oral sumatriptan (l00 mg) in the acute treatment of migraine. Cephalalgia. 16:1996;368-369.
41. Kaube H., Hoskin K.L., Goadsby P.J. Sumatriptan inhibits central trigeminal neurons only after blood-brain barrier disruption. Br. J. Pharmacol. 109:1993;788-792.
42. Knight Y.E., Edvinsson L., Goadsby P.J. Blockade of release of CGRP after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288. Cephalalgia. 17:1997;248.
43. 1B/1D receptor. Cephalalgia. 17:1997;403.
44. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain. 117:1994;199-210.
45. + current. Naunyn-Schmiedeberg's Arch. Pharmacol. 358:1998;608-615.
46. Lee W.S., Moskowitz M.A. Conformationally restricted sumatriptan analogues CP-122,288 and CP-122,638, exhibit enhanced potency against neurogenic inflammation in aura mater. Brain Res. 626:1993;303-305.
47. Lee W.S., Moussaoui S.M., Moskowitz M.A. Blockade by oral or parenteral RPR100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation in guinea-pig aura mater and conjunctiva. Br. J. Pharmacol. 112:1994;920-924.
48. Limmroth V., Wermelskirchen D., Tegtmeier F., Diener H.C. R91274 (alniditan) blocks neurogenic inflammation in the rat meninges more effectively than sumatriptan by activation of SHTlD-receptors. Neurology. 48:1997;1137.
49. Liu-Chen, L.Y., Han, D.H. and Moskowitz, M.A., Pia arachnoid contains substance originating from trigeminal neurons, Neuroscience, 9 (1983a) 803-808.
50. Liu-Chen, L.Y., Mayberg, M.R. and Moskowitz, M.A., Immunohistochemical evidence for a substance P-containing trigeminovascular pathway to pial arteries in cats, Brain Res., 268 (1983b) 162-166.
51. Liu-Chen L.Y., Gillespie S.A., Norregaard T.V., Moskowitz M.A. Co localization of retrogradely transported wheat germ agglutinin and the putative neurotransmitter substance P within trigeminal ganglion cells projecting to cat middle cerebral. J. Comp. Neurol. 225:1984;187-192.
52. Magnusson K.R., Larson A.A., Madl J.E., Altschuler R.A., Beitz A.J. Colocalization of fixative-modified glutamate and glutaminase in neurons of the spinal trigeminal nucleus of the rat: an immunohistochemical and immunoradiochemical analysis. J. Comp. Neurol. 247:1986;477-490.
53. Markowitz S., Saito K., Moskowitz M.A. Neurogenically mediated leakage of plasma proteins occurs from blood vessels in aura mater but not brain. J. Neurosci. 7:1987;4129-4136.
54. Markowitz S., Saito K., Moskowitz M.A. Neurogenically mediated plasma-extravasation in aura mater: effect of ergot alkaloids, A possible mechanism of action in vascular headache. Cephalalgia. 8:1988;83-91.
55. 1B/D agonist for treatment of migraine: mechanism of action. Neurology. 48:1997;11-31.
56. 1B/1D receptor partial agonist, 31IC90 (zolmitriptan). Br. J. Pharmacol. 121:1997;157-164.
57. Maura G., Marcoli M., Tortarolo M., Andrioli G.C., Raiteri M. Glutamate release in human cerebral cortex and its modulation by 5-hydroxytryptamine acting at h 5-HT1D receptors. Br. J. Pharmacol. 123:1998;45-50.
58. May A., Gijsman H.J., Wallnoefer A., Jones R., Diener H.C., Ferrari M.D. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain. 67:1996;375-378.
59. Mitsikostas D.D., Sanchez del Rio M., Wacber C., Moskowitz M.A., Cutrer F.M. The NMDA receptor antagonist MK-801 reduces capsaicin-induced cfos expression within rat trigeminal nucleus caudalis. Pain. 76:1998;239-248.
60. Moskowitz M.A. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol. Sci. 13:1992;307-311.
61. Moskowitz M.A., Brody M., Liu-Chen L.Y. In vitro release of immunoreactive substance P from putative afferent nerve endings in bovine pie arachnoid. Neuroscience. 9:1983;809-814.
62. Moskowitz M.A., Cutrer F.M. Sumatriptan: a receptor-targeted treatment for migraine. Ann. Rev. Med. 44:1993;145-154.
63. Norman B., Panebianco D., Block G.A. A placebo-controlled. in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine. Cephalalgia. 18:1998;407.
64. 1F receptors- binding affinities. brain penetration and activity in the neurogenic aural inflammation model of migraine. Life Sci. 61:1997;2117-2126.
65. Rance D., Clear N., Dallman L., Llewellyn E., Nuttall J., Verrier H. Physicochemical comparison of eletriptan and other 5-HT 1D-like agonists as a predictor of oral absorption potential. Headache. 37:1997;328.
66. Rexed B. A cytoarchitectonic atlas of the spinal cord in the cat. J. Comp. Neurol. 96:1954;297-380.
67. Roon K., Diener H.C., Ellis P., Hettiarachchi J., Poole P., Christiansen I., Ferrari M.D., Olesen J. CP-122,288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: results of two controlled clinical studies. Cephalalgia. 17:1997;245.
68. Ryan R.E., Elkind A., Goldstein J. Twenty-four hour effectiveness of BMS 180048 in the acute treatment of migraine headaches. Headache. 37:1997;245-248.
69. 1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential. Naunyn Schmiedeberg's Arch. Pharmacol. 354:1997;295-302.
70. Shepheard S.L., Williamson D.J., Williams J., Hill R.G., Hargreaves R.J. Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in the aura mater and c-fos mRNA expression in the trigeminal nucleus caudalis of rats. Neuropharmacology. 34:1995;255-261.
71. Siegel, S., Non-parametric statistics for the behavioural sciences, McGraw-Hill, Tokyo, 1956.
72. Storer, R.J. and Goadsby, P.J., Trigeminovascular nociceptive transmission involves NMDA and non-NMDA glutamate receptors, Neuroscience (1999) in press.
73. Tran-Dinh Y.R., Thurel C., Cunin G., Serrie A., Seylaz J. Cerebral vasodilation after the thermocoagulation of the trigeminal ganglion in humans. Neurosurg. 31:1992;658-662.
74. Williamson D.J., Shepheard S.L., Hill R.G., Hargreaves R.J. The novel anti-migraine agent rizatriptan inhibits neurogenic aural vasodilatation and extravasation. Eur. J. Pharmacol. 328:1997;61-64.
75. 1D antagonist properties. Cephalalgia. 17:1997;404.
76. Yu X.J., Waeber C., Castanon N., Scearce K., Hen R., Macor J.E., Chaveau J., Moskowitz M.A. 5-carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl-tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine 1B receptors. Mol. Pharmacol. 49:1996;761-765.